PARTNERSHIP OPPORTUNITIES
Free Shipping in the U.S. for orders over $1000. Shop Now>>
CD30, also known as tumor necrosis factor receptor superfamily member 8 (TNFRSF8), is a cell surface protein encoded by the TNFRSF8 gene. Located on chromosome 1p36.23, the TNFRSF8 gene codes for a protein with 595 amino acids. CD30 has a molecular weight of approximately 120 kDa. Post-translational modifications of CD30 include phosphorylation, glycosylation, and the formation of disulfide bonds, which can influence its function and interactions with other molecules. CD30 is primarily a membrane protein that plays a crucial role in modulating immune responses, particularly in T cell activation and differentiation, as well as in the regulation of apoptosis and cell survival.
CD30 is predominantly expressed in lymphoid tissues such as lymph nodes, spleen, and thymus, as well as in activated T cells and B cells. The expression of CD30 is tightly regulated and can be induced by various stimuli, including cytokines, antigens, and cellular stress. Aberrant expression of CD30 has been associated with various diseases and conditions, including autoimmune diseases, infectious diseases, and cancer. Notably, CD30 is highly expressed in certain lymphomas, such as Hodgkin lymphoma and anaplastic large-cell lymphoma, where it serves as a diagnostic marker and potential therapeutic target.
CD30 expression can also provide diagnostic and prognostic information about certain cancers, particularly lymphomas. For example, in Hodgkin lymphoma, CD30 is highly expressed on the surface of Reed-Sternberg cells, which are characteristic tumor cells in this type of lymphoma. CD30 immunohistochemistry is commonly used as a diagnostic marker to confirm the presence of Hodgkin lymphoma and distinguish it from other lymphoproliferative disorders. Additionally, CD30 expression levels in Hodgkin lymphoma have been associated with disease stage and response to treatment, providing prognostic information that can guide patient management decisions. In anaplastic large cell lymphoma (ALCL), CD30 is a defining marker, and immunohistochemistry is used to diagnose ALCL, distinguishing it from other types of non-Hodgkin lymphomas. Moreover, CD30 expression levels in ALCL have been correlated with disease aggressiveness and response to treatment, serving as a prognostic indicator for patient outcomes.
Several monoclonal antibodies targeting CD30 and antibody-drug conjugates (ADCs) have also been developed for cancer therapy. For example, Brentuximab vedotin (Adcetris®) consists of a CD30-specific monoclonal antibody linked to a potent cytotoxic agent, MMAE. It has been FDA-approved for relapsed or refractory Hodgkin lymphoma and systemic anaplastic large-cell lymphoma. Additionally, AFM13, a bispecific CD30/CD16A antibody, is another promising candidate under investigation for CD30-expressing lymphomas. These therapeutic approaches demonstrate diverse strategies, from directly delivering cytotoxic payloads to engaging the immune system, aiming to improve outcomes for patients with CD30-positive malignancies. Ongoing research and clinical trials continue to explore the full potential of CD30-directed therapies in cancer treatment.
NeoBiotechnologies offers a variety of antibodies against CD30 that have been validated for flow cytometry, immunofluorescence, and immunohistochemistry. Additionally, we hold exclusive rights to CD30 antibodies available for licensing or collaboration [https://www.neobiotechnologies.com/gene-name/tnfrsf8/].
Tumor necrosis factor receptor superfamily member 8, CD30L receptor, Ki-1 antigen, Lymphocyte activation antigen CD30, CD30L receptor, Cytokine receptor CD30, Ki-1 antigen, Lymphocyte activation antigen CD30, Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
Cardiovascular, Immunology, AKT Signaling, Cytokine Signaling
Showing all 13 results
Showing all 13 results
